Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Little evidence that live herpes zoster vaccine eligibility reduces hospital-coded dementia in England: a regression discontinuity analysis of 6.3 million individuals.

In=person event at the Schwarzman Centre, Chaired by Professor Sir Aziz Sheikh, Head of Department

Following an influential study in Wales, they examined whether eligibility for the live herpes zoster vaccine reduces dementia risk in England using a regression discontinuity design based on the 2013 UK rollout. An analysis of over 6.3 million individuals using Hospital Episode Statistics data confirmed that vaccine eligibility significantly reduced hospital-coded herpes zoster, validating the study design. However, there was no evidence of a corresponding reduction in hospital-coded dementia, with results remaining null across multiple sensitivity analyses. Additional checks found no substantial bias or confounding that could explain the discrepancy with earlier studies suggesting protective effects, and possible reasons for the discrepancy will be discussed. Overall, the findings suggest that while the vaccine effectively reduces zoster incidence, any impact on dementia risk in England is likely small or absent.  

Register here: Registration Guest Lecture Series 17 June 2026